Viridian Therapeutics Q1 2024 GAAP EPS $(0.79) Beats $(1.10) Estimate, Sales $72.000K Beat $71.182K Estimate
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics (NASDAQ:VRDN) reported Q1 2024 earnings with a GAAP EPS of $(0.79), surpassing the $(1.10) estimate, and sales of $72,000, slightly above the $71,182 estimate. This represents a significant improvement in EPS from the previous year, though sales have decreased.
May 08, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics reported a better-than-expected Q1 2024 EPS of $(0.79) and sales of $72,000, indicating a strong performance against estimates.
The positive earnings surprise and sales beat for Viridian Therapeutics suggest a bullish sentiment in the short term. Beating EPS estimates by 28.18% and sales estimates, albeit marginally, indicates operational efficiency and potential for growth. The improvement in EPS compared to the previous year further strengthens the case for a positive outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100